IVA Inventiva SA

Statement of total voting rights and shares forming the company’s share capital as October 20, 2025

Statement of total voting rights and shares forming the company’s share capital as October 20, 2025

 Article R. 22-10-23 of the French Commercial Code

 Market : Euronext Paris

ISIN code / Mnemo : FR0013233012 / IVA

Web site :



 



Date 		Number of Shares Outstanding

 



Total voting rights,

gross (1)

 



Total voting rights,

net (2)
October 20th, 2025 145 951 274 158 653 570 158 594 019

(1)   The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.



(2)   The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the public is properly informed.



About Inventiva



Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. 

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).

Contacts 

Inventiva

Pascaline Clerc

EVP, Strategy and Corporate Affairs



 ICR Healthcare

Media Relations

Alexis Feinberg 



ICR Healthcare

Investor relations

Patricia L. Bank



Attachment



EN
06/11/2025

Underlying

IVAInventiva SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Inventiva SA

 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva to Participate in Four Upcoming March Investor Conferences

Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2,...

February 26, 2026 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva participera à quatre conférences investisseurs en mars

Inventiva participera à quatre conférences investisseurs en mars  Daix (France), New York (États-Unis), le 26 février 2026 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que la direction de la Société participera à des réunions individuelles et à des présentations lors des événements investisseurs suivants : TD Cowen 46ème Health Care Conference – 2 au 4 mars 2026Date : lun...

February 26, 2026 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva to Participate in Four Upcoming March Investor Conferences

Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2,...

February 26, 2026 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva to Participate in Four Upcoming March Investor Conferences

Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapie for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2...

February 26, 2026 1 EN
Mathijs Geerts Danau
  • Mathijs Geerts Danau
IVA INVENTIVA SA

Inventiva FIRST LOOK: preliminary FY25 results hold no surprises

Inventiva reported preliminary FY25 results which hold no surprises, and confirmed its cash-runway guidance, which following the € 149m capital raise announced in November 2025, extends the company's runway to middle of 1Q27. This provides funding beyond the expected topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which are expected in 2H26. We reiterate our Buy rating and € 7 TP.

02/17/26 February 17, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch